Exact Sciences (EXAS)
(Delayed Data from NSDQ)
$49.67 USD
+2.62 (5.57%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $49.67 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value F Growth A Momentum D VGM
Brokerage Reports
0 items in cart
Exact Sciences Corporation [EXAS]
Reports for Purchase
Showing records 221 - 240 ( 367 total )
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Publication of Full DEEP-C Data Supportive of Positive FDA Review Next Week, Market Uptake
Provider: The Benchmark Company
Analyst: WALD J
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
LIFE SCIENCES AND HEALTH CARE-The Week Ahead in Life Sciences - Upcoming Events for the Week of March 10
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Morning Call
Provider: The Benchmark Company
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
4Q As Expected Publication, Panel, and Commercial Prep in Focus
Provider: Roth Capital Partners, Inc.
Analyst: LEWIS C
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Ready for Launch, Price Target Increase As Model Reflects Another Year of Sales
Provider: The Benchmark Company
Analyst: WALD J
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
4Q13 Recap - Good Tone on Imminent Publication & Reimbursement - Contract Sales Partner Announced & Economics Seem Better - Maintain OP - PT to $15
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Expecting Uneventful 4Q13 Earnings - Pivotal Publication Any Day & FDA March Panel Meeting Key - Raising PT to $14 - Maintain OP
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Preannouncement Watch - Look for Med Tech News into Next Week?s HC Conference
Provider: Roth Capital Partners, Inc.
Analyst: LEWIS C
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.